- Report
- February 2025
- 100 Pages
Global
From €5447EUR$5,950USD£4,629GBP
- Report
- April 2025
- 175 Pages
Global
From €4110EUR$4,490USD£3,493GBP
- Report
- April 2025
- 175 Pages
Global
From €4110EUR$4,490USD£3,493GBP
- Report
- March 2025
- 200 Pages
Global
From €4110EUR$4,490USD£3,493GBP
- Report
- February 2025
- 183 Pages
Global
From €4119EUR$4,500USD£3,501GBP
- Report
- November 2019
- 150 Pages
Global
From €1259EUR$1,375USD£1,070GBP
€2517EUR$2,750USD£2,139GBP
- Report
- June 2021
- 50 Pages
China
From €2380EUR$2,600USD£2,023GBP
- Report
- January 2024
- 200 Pages
Global
From €3799EUR$4,150USD£3,229GBP
- Report
- October 2023
- 81 Pages
United Kingdom
From €3204EUR$3,500USD£2,723GBP
- Report
- March 2023
- 111 Pages
Global
From €4119EUR$4,500USD£3,501GBP
- Report
- January 2024
- 129 Pages
United States
€3479EUR$3,800USD£2,956GBP
- Drug Pipelines
- January 2022
- 30 Pages
Global
From €458EUR$500USD£389GBP
Taxotere is a chemotherapy drug used to treat non-small cell lung cancer (NSCLC). It is a type of drug known as a taxane, which works by interfering with the growth of cancer cells. Taxotere is typically used in combination with other drugs, such as cisplatin or carboplatin, to increase the effectiveness of treatment. It is also used to treat other types of cancer, such as breast cancer and ovarian cancer.
Taxotere is available in both oral and intravenous forms, and is typically administered in cycles of three weeks. Common side effects of Taxotere include nausea, vomiting, hair loss, and fatigue.
The Taxotere market is highly competitive, with a number of companies offering similar products. Some of the major players in the market include Sanofi, Pfizer, Bristol-Myers Squibb, AstraZeneca, and Merck. Show Less Read more
